Study of Sirolimus Effects on Brain Blood Flow in Middle-Aged Women with ApoE4 Gene
Led by University of Missouri-Columbia · Updated on 2026-10-05
225
Participants Needed
1
Research Sites
27 weeks
Total Duration
AI-Summary
What This Trial Is About
Alzheimers disease is a severe brain condition marked by harmful clumps and fibers in the brain, with no current cure. This trial studies sirolimus, an FDA-approved drug that might improve brain blood flow and energy use. It focuses on women aged 45 to 65 who carry the ApoE4 gene, which raises Alzheimers risk. The study is randomized and placebo-controlled to compare sirolimus with a non-medicine pill.
Participants will be randomly assigned to receive either sirolimus or a placebo daily by mouth for about 4 weeks. The trial includes three visits over 12 weeks. During the study, participants will complete questionnaires, undergo genetic testing for the ApoE4 gene, provide blood samples and vital signs, and have two MRI scans to measure brain blood flow and other brain functions.
Throughout the study, participants will keep a diary to record when they take the study drug or placebo. Researchers will measure changes in cerebral blood flow using MRI from baseline to 4 weeks as the primary outcome. Secondary outcomes include blood markers, brain connectivity by fMRI, blood brain barrier integrity, brain oxygenation, and glucose uptake by PET imaging. Safety and adherence will be monitored during the trial period.
CONDITIONS
Brief Title
Effects of Sirolimus on Asymptomatic ApoE4 Carriers
Research Team
K
Kim Ray
N
Nathan Bresette
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Sirolimus (rapamycin)
Placebo
What is it?
An mTOR inhibitor drug, studied here to see if it can affect brain blood flow and Alzheimer's-related biomarkers in women with the APOE4 gene but no cognitive symptoms.
A look-alike pill with no active drug, used to compare against sirolimus to see true effects absent treatment.
Role in the trial
The intervention group, assigned to receive sirolimus to measure effects on brain blood flow and Alzheimer's biomarkers.
The control group, receiving placebo, to allow unbiased comparison of sirolimus effects.
Primary use
Investigated for its potential to modify brain blood flow and biomarkers related to Alzheimer's risk in cognitively normal APOE4-positive women.
Used as a comparison to determine if changes seen with sirolimus are due to the drug and not other factors.
How is it given or performed?
Sirolimus is taken by mouth daily for 4 weeks.
Placebo is taken by mouth daily for 4 weeks under the same schedule as the drug group.
Evidence status
Benefits and risks of sirolimus for this preventive purpose have not been established; early studies suggest it may affect immune, vascular, and Alzheimer’s-related pathways, but effects in asymptomatic APOE4-positive women are not yet known.
Placebo provides a baseline for measuring biological and cognitive changes, but offers no therapeutic benefit.
Important limitations
Long-term effects and safety of sirolimus for Alzheimer’s prevention are unknown; possible immune, metabolic, and infection risks require more study. Only short-term outcomes (4 weeks) are examined in this trial.
The placebo group does not inform about effects or risks outside the context of the current trial and offers no active intervention.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 45Years - 65Years
FEMALE
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Willing and able to provide informed consent
Assigned female at birth
Age between 45 and 65 years
Able to perform self-care and daily activities with little or no help
Post-menopausal or using highly effective contraception
Body weight of at least 40 kg
Able to communicate effectively and follow study instructions
You will not qualify if you...
Diagnosis of mild cognitive impairment, dementia, or Alzheimer's disease
Body mass index of 35 or higher
Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c 6.5% or greater)
History of skin ulcers or poor wound healing
Current tobacco, illicit drug use, or alcohol abuse
Use of anti-platelet or anti-coagulant drugs other than aspirin
Use of medications affecting CYP3A4 or cerebral blood flow
Immunosuppressant therapy within the last year
Chemotherapy or radiation within the last year
Current or chronic liver or kidney disease
Untreated high triglycerides (fasting triglycerides less than 300 mg/dl required)
Significant pulmonary disease
Chronic heart failure
Pregnancy or breastfeeding
Recent heart attack, coronary disease, stroke, or transient ischemic attack
Poorly controlled blood pressure (systolic over 160 or diastolic over 100 mmHg)
Active inflammatory, autoimmune, infectious, mental illness, or COVID-19
Brain lesions or abnormalities seen on MRI or CT
Organ transplant recipients
History of stroke or ruptured brain aneurysm
Recent malignancy except certain localized cancers
History of epilepsy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
3 study visits over 12 weeks
Treatment
Duration - 4 weeks
Participants take either sirolimus or a placebo pill daily for approximately 4 weeks while completing diary records and undergoing assessments.
Three study visits during treatment period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Randomized Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Dose REGN22044 by IV or Subcutaneous Injection in Healthy Adults
Phase 1 Study to Test Safety and Response to Single and Multiple Doses of MT-201 in Healthy Adults Aged 19 to 55
Phase 1 Randomized Study of S-1117 Given by Injection in Healthy Adults Ages 18 to 65
Phase 1, Randomized, Double-Blind Study of S-4321 with Single and Multiple Doses in Healthy Adults
A Multi-Center Study to Develop a Multi-Cancer Early Detection Test Using Whole Genome Sequencing of Circulating DNA in Cancer Patients and Healthy Volunteers
Investigation of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics of Single Administrations of NNC9733-0001 in Healthy Participants and in Participants With Type 2 Diabetes
Phase 1 Study to Evaluate Safety and Effects of TL-003 Given by IV in Healthy Adults and People With Ulcerative Colitis
Phase 1 Open-Label Study of MT-201 with Infliximab in Healthy Adults Evaluating Safety and Immune Response
Phase 0 Trial of Copper-64 Labeled Granzyme B PET Radiotracers to Study Pharmacokinetics and Safety in Healthy Adults
Phase 1 Study of UA026 Tablets to Assess Safety, Tolerability, and Effects in Healthy Adults and Adults With Moderate to Severe Plaque Psoriasis
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers.